Bain Capital Life Sciences
Boston, Massachusetts, United StatesFounded 2016
Bain Capital Life Sciences (BCLS) is a life sciences-focused investment firm founded in 2016 as part of Bain Capital. It invests in biopharmaceutical, medical device, diagnostic, and life science tool companies across the globe, targeting companies that drive medical innovation to improve the lives of patients with unmet medical needs.
51% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $168.4M (across 93 rounds with reported amounts).
Portfolio
71
Fund Size
$3B
Top Stage
Series B
Last 12 Mo
6
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
101 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 OMass Therapeutics | Series C | $310M | Oct 2026 |
 Aiolos | Series A | $245M | Sep 2026 |
 Merida Biosciences | Series A | $121M | Aug 2026 |
 Beeline Medicines | Series A | — | Jun 2026 |
| CCereVasc, Inc. | Series C | $85M | Jun 2026 |
| Beeline Medicines | Series A | $300M | Apr 2026 |
| CCereVasc, Inc. | Series C | $85M | Jan 2026 |
| AAngitia Bio | Series D | $130M | Jan 2026 |
 Angitia Biopharmaceuticals | Series D | $130M | Jan 2026 |
| KKailera | Series B | $600M | Oct 2025 |
 Kailera Therapeutics | Series B | $600M | Oct 2025 |
 Seran Bioscience | Series C | $200M | Sep 2025 |
 Apreo Health | Series B | $130M | Sep 2025 |
 Apreo Health | Series B | $130M | Sep 2025 |
 Atsena Therapeutics | Series C | $150M | Apr 2025 |
 Abcuro, Inc. | Series C | $200M | Feb 2025 |
 Timberlyne Therapeutics | Series A | $180M | Jan 2025 |
| Apreo Health | Series B | $130M | Jan 2025 |
| AApreo | Unknown | $130M | Jan 2025 |
| Apreo Health | Series B | $130M | Jan 2025 |
| Kailera Therapeutics | Series A | — | Oct 2024 |
| Seran Bioscience | Growth | $200M | Sep 2024 |
 Cardurion Pharmaceuticals | Series B | $260M | Jul 2024 |
| CCereVasc, Inc. | Series B | $70M | May 2024 |
 Cidara Therapeutics | Unknown | $240M | Apr 2024 |
Page 1 of 5
Top Co-Investors
RA Capital Management37 shared
Cormorant Asset Management15 shared
Redmile Group14 shared
BlackRock Private Equity Partners13 shared
Wellington Management13 shared
Perceptive Advisors12 shared
Atlas Venture11 shared
Logos Capital11 shared
Omega Funds11 shared
OrbiMed11 shared
SV Health Investors10 shared
T. Rowe Price9 shared
GV9 shared
Rock Springs Capital9 shared
Longitude Capital9 shared
Adage Capital Management9 shared
Foresite Capital9 shared
Viking Global Investors8 shared
Sanofi Ventures8 shared
Vivo Capital8 shared
Last updated: 20 October 2026